IDEXX Updates Executive Compensation; Filed 8-K on 2026-03-26

TL;DR

**IDEXX just updated executive pay, filed an 8-K on 2026-03-26.**

AI Summary

IDEXX Laboratories Inc. filed an 8-K on March 26, 2026, reporting changes in its executive compensation structure under Item 5.02. This filing indicates that the company is updating how certain officers are compensated, which could impact future financial performance and executive retention. For investors, understanding these changes is crucial as executive compensation can influence leadership stability and the company's overall financial health, potentially affecting stock valuation.

Why It Matters

Changes in executive compensation can signal shifts in company strategy or performance incentives, directly impacting leadership motivation and the company's financial outlook.

Risk Assessment

Risk Level: medium — Changes in executive compensation can introduce both positive and negative risks depending on the specifics, which are not fully detailed in this summary filing.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the compensatory arrangements mentioned in Item 5.02 to assess their potential impact on IDEXX's financial health and executive retention.

Key Players & Entities

• IDEXX LABORATORIES INC /DE (company) — Filer of the 8-K
• 0000874716 (company) — CIK of IDEXX LABORATORIES INC /DE
• 2026-03-26 (date) — Filing and Acceptance Date
• 2026-03-24 (date) — Period of Report

Forward-Looking Statements

• IDEXX will provide more detailed information on the specific compensatory arrangements in future filings or investor calls. (IDEXX LABORATORIES INC /DE) — medium confidence, target: 2026-06-30

FAQ

Key Financial Figures

• $0.10 — ange on whichregistered Common Stock, $0.10 par value per share IDXX NASDAQ Glo
• $1,230,000 — ration Date, in the aggregate amount of $1,230,000; (ii) Dr. Hunt's target annual bonus fo
• $984,000 — r two years, in the aggregate amount of $984,000, payable together with the salary conti
• $50,000 — n payments, (iii) a lump-sum payment of $50,000, representing 78 weeks of COBRA premium
• $10,000 — ; (iv) transition assistance benefit of $10,000; and (v) reimbursement of tax preparati
• $6,000 — 26 tax years in an amount not to exceed $6,000 per tax year (to the extent not reimbur

Filing Documents

• tm269826d1_8k.htm (8-K) — 35KB
• tm269826d1_ex10-1.htm (EX-10.1) — 87KB
• tm264623d1_8kimg01.jpg (GRAPHIC) — 7KB
• 0001104659-26-034906.txt ( ) — 321KB
• idxx-20260324.xsd (EX-101.SCH) — 3KB
• idxx-20260324_lab.xml (EX-101.LAB) — 33KB
• idxx-20260324_pre.xml (EX-101.PRE) — 22KB
• tm269826d1_8k_htm.xml (XML) — 3KB

02. Departure of Directors or Certain

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24, 2026, IDEXX Laboratories, Inc. ("IDEXX") and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the "Separation Date") and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the "Final Employment Date"). IDEXX and Dr. Hunt entered into a separation letter agreement (the "Separation Agreement") to memorialize the terms of Dr. Hunt's advisory role and subsequent departure. Pursuant to the Separation Agreement, IDEXX will pay to Dr. Hunt separation benefits in the form of (i) salary continuation for 104 weeks following the Separation Date, in the aggregate amount of $1,230,000; (ii) Dr. Hunt's target annual bonus for two years, in the aggregate amount of $984,000, payable together with the salary continuation payments, (iii) a lump-sum payment of $50,000, representing 78 weeks of COBRA premium costs with respect to Dr. Hunt's continued coverage under the IDEXX medical, dental and/or vision plans; (iv) transition assistance benefit of $10,000; and (v) reimbursement of tax preparation or financial planning services for the 2025 and 2026 tax years in an amount not to exceed $6,000 per tax year (to the extent not reimbursed prior to the Separation Date). Vesting of stock option, restricted stock unit and performance stock unit awards previously issued to Dr. Hunt under IDEXX's stock incentive plans will cease effective as of the Final Employment Date, and all unvested awards will be forfeited. Dr. Hunt's stock option awards, to the extent vested and exercisable, will remain exercisable during the period following the Final Employment Date that is specified in the applicable award agreements. Dr. Hunt's position with IDEXX is being eliminated, and,

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 10.1 Separation Agreement by and between Nimrata Hunt, PhD, and IDEXX Laboratories, Inc., dated March 24, 2026. 104 Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: March 25, 2026 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR